Facioscapulohumeral muscular dystrophy (FSHD) represents the third most common form of muscular dystrophy and is characterized by muscle weakness and atrophy. FSHD is caused by the altered expression of the transcription factor double homeobox 4 (DUX4), which is involved in several significantly altered pathways required for myogenesis and muscle regeneration. While DUX4 is normally silenced in the majority of somatic tissues in healthy individuals, its epigenetic de-repression has been linked to FSHD, resulting in DUX4 aberrant expression and cytotoxicity in skeletal muscle cells. Understanding how DUX4 is regulated and functions could provide useful information not only to further understand FSHD pathogenesis, but also to develop therapeutic approaches for this disorder. Therefore, this review discusses the role of DUX4 in FSHD by examining the possible molecular mechanisms underlying the disease as well as novel pharmacological strategies targeting DUX4 aberrant expression.

Duranti, E., Villa, C. (2023). Influence of DUX4 Expression in Facioscapulohumeral Muscular Dystrophy and Possible Treatments. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 24(11) [10.3390/ijms24119503].

Influence of DUX4 Expression in Facioscapulohumeral Muscular Dystrophy and Possible Treatments

Duranti E.
Primo
;
Villa C.
Ultimo
2023

Abstract

Facioscapulohumeral muscular dystrophy (FSHD) represents the third most common form of muscular dystrophy and is characterized by muscle weakness and atrophy. FSHD is caused by the altered expression of the transcription factor double homeobox 4 (DUX4), which is involved in several significantly altered pathways required for myogenesis and muscle regeneration. While DUX4 is normally silenced in the majority of somatic tissues in healthy individuals, its epigenetic de-repression has been linked to FSHD, resulting in DUX4 aberrant expression and cytotoxicity in skeletal muscle cells. Understanding how DUX4 is regulated and functions could provide useful information not only to further understand FSHD pathogenesis, but also to develop therapeutic approaches for this disorder. Therefore, this review discusses the role of DUX4 in FSHD by examining the possible molecular mechanisms underlying the disease as well as novel pharmacological strategies targeting DUX4 aberrant expression.
Articolo in rivista - Review Essay
DUX4; facioscapulohumeral muscular dystrophy; muscle differentiation;
English
30-mag-2023
2023
24
11
9503
open
Duranti, E., Villa, C. (2023). Influence of DUX4 Expression in Facioscapulohumeral Muscular Dystrophy and Possible Treatments. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 24(11) [10.3390/ijms24119503].
File in questo prodotto:
File Dimensione Formato  
10281-424501_VoR.pdf

accesso aperto

Tipologia di allegato: Publisher’s Version (Version of Record, VoR)
Licenza: Creative Commons
Dimensione 1.97 MB
Formato Adobe PDF
1.97 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/424501
Citazioni
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
Social impact